

GENENTECH AT A GLANCE

Genentech pioneered the biotech industry and revolutionized how we treat some of the world's most complex health challenges.

For nearly 50 years, we've been deeply committed to enhancing the lives of patients everywhere. Whether it's changing the outlook for one of the most aggressive types of breast cancer, pioneering treatments for a debilitating form of multiple sclerosis, or providing life-changing therapies for those facing vision loss, our mission remains steadfast.

Today, as a member of the Roche Group, we remain dedicated to pursuing breakthrough research, developing life-changing medicines, unlocking advances in data and technology, and partnering across society to take on systemic issues that stand in the way of better healthcare for all. To accelerate R&D and further enhance therapeutic outcomes, we're leveraging cutting-edge artificial intelligence capabilities.

FOSTERING INNOVATION

NEARLY \$15 BILLION

INVESTED GLOBALLY IN R&D EACH YEAR, REPRESENTING ONE OF THE LARGEST R&D BUDGETS IN THE INDUSTRY

MORE THAN 80

INVESTIGATIONAL MEDICINES IN CLINICAL DEVELOPMENT, REPRESENTING ONE OF THE LARGEST PIPELINES IN THE INDUSTRY

40

FDA BREAKTHROUGH THERAPY DESIGNATIONS FOR MEDICINES THAT HAVE THE POTENTIAL TO PROVIDE SUBSTANTIAL IMPROVEMENT OVER CURRENTLY AVAILABLE TREATMENTS

MORE THAN 40

MEDICINES ON THE MARKET TO TREAT PEOPLE LIVING WITH SERIOUS DISEASES

22.8 MILLION

PATIENTS WORLDWIDE TREATED WITH ONE OF OUR MEDICINES IN 2023

650

ACTIVE CLINICAL TRIALS WORLDWIDE, WITH MORE THAN 270 ACTIVE CLINICAL TRIALS IN THE UNITED STATES

INVESTING IN AMERICA

Genentech is proud to have pioneered the processes and technologies to commercially manufacture biologics at our South San Francisco campus in 1983.

Since then, we have continued to innovate the way medicines are made, including taking a long-term view to evolve and modernize our manufacturing capabilities to meet the needs of patients in the future.

After more than four decades at the forefront of biologics manufacturing innovation, we are proud to continue investing in the long-term growth and viability of manufacturing in the United States. The Roche Group in the U.S. comprises several companies, including Roche Diagnostics, Genentech, Flatiron Health, Foundation Medicine, and Spark Therapeutics. The U.S. is Roche's largest country in terms of personnel, R&D, manufacturing, and plants and equipment.

FOUR

R&D, MANUFACTURING AND
DISTRIBUTION SITES IN THE U.S.

\$5 BILLION

INVESTED IN INFRASTRUCTURE OVER THE
PAST DECADE

NEARLY 29,000

COMBINED ROCHE AND GENENTECH
EMPLOYEES IN THE U.S. INCLUDING 4,000
MANUFACTURING JOBS

PIONEERING INCLUSIVE HEALTH SOLUTIONS

We envision a healthcare system that is diverse, inclusive, accountable and trustworthy to patients. To achieve this vision, we advance a more equitable and just healthcare system, diversify the scientific and medical workforce, and collaborate across our industry and the communities we serve to ensure all communities thrive.

CLINICAL TRIAL DESIGN

We must ensure clinical trial participants are more representative of the entire patient population. At Genentech, we are testing recruitment and retention approaches and establishing best practices that can be leveraged across the industry to help advance inclusive research.

OUR ACTIONS

In 2021, we launched the Advancing Inclusive Research® Site Alliance, a coalition of clinical research sites collaborating with us to advance the representation of diverse patient populations in our clinical studies.



Our founding alliance sites are now recruiting Black & Hispanic/Latinx patients **two times faster** than other sites on the same studies.

PARTNERING WITH COMMUNITIES

We are investing in collaborative initiatives that support and center the needs of historically underserved communities to remove barriers to care and improve health outcomes.

OUR ACTIONS

We are engaging with **more than 500** patient advocacy and community-based organizations across the U.S. that lead transformative and community-driven solutions to long-standing inequities in healthcare.



Together with the American Diabetes Association, we have supported programs to address access to eye screenings and treatment to **more than 4,100** community members in Birmingham, AL, through the Health Equity Now initiative, which aims to increase equitable access to eye health care.



Through our corporate membership support of the American Cancer Society, **more than 1.2 million** new screenings were conducted.



MORE THAN 16,000

CANCERS DIAGNOSED THAT MAY NOT HAVE OTHERWISE BEEN FOUND.

INVESTING IN COMMUNITIES

Since 2017, Genentech has invested **more than \$230 million** in equity-focused giving alone, **more than 80%** of which supports initiatives that tackle disparities in the health-care and education systems, serve patients directly, advance patient-centered policy solutions, and advance diversity in STEM.

OUR ACTIONS

Genentech has dedicated **\$79 million** to dismantle systemic barriers to careers in STEM and medicine for traditionally underrepresented groups, from kindergarten to careers.



In 2019, we established the Genentech Health Equity Innovation Fund to support groundbreaking initiatives aimed at transforming health-care and addressing systemic inequities that disproportionately affect patients of color.



NEARLY \$50 MILLION

COMMITTED TO INITIATIVES FOCUSED ON TACKLING THE OFTEN-OVERLOOKED DRIVERS OF HEALTH INEQUITIES.

COMMITMENT TO RESPONSIBLE PRICING AND PATIENT ACCESS

Socially responsible pricing is everyone's responsibility. At Genentech, we are dedicated to pushing the boundaries of science to develop innovative therapies that improve patient outcomes in areas of significant unmet need. Our dedication doesn't stop there.

IMPLEMENTING RESPONSIBLE PRICING ACTIONS

We are committed to socially responsible business practices that deliver affordable, accessible, and meaningful healthcare solutions. Our pricing models are designed to reflect the value our medicines deliver to patients and society and the critical importance of ensuring patients have broad and equitable access.

OUR ACTIONS

We take the responsibility of pricing our medicines very seriously – all while preserving our ability to sustain robust R&D investments that will drive the next medical breakthroughs.



Over the last decade, we've launched **20** breakthrough medicines in areas of great need for innovation, and we've priced these medicines at or below - in some cases significantly below - other available medicines approved by the FDA to treat the same disease.

ENSURING PATIENT ACCESS TO MEDICINES

Living with a serious illness can come with many challenges. Getting the medicine you need shouldn't be one of them. In the mid-1980s, we recognized the need to help patients and caregivers navigate complex healthcare systems so that they could start and stay on the Genentech medicines they were prescribed.

OUR ACTIONS

We believe every person should get the Genentech medicine they need regardless of their ability to pay and we offer several support services to make this happen. Over the past 27 years, Genentech has helped **more than 3.3 million** people get the medicines they need through patient assistance programs.



In 2023, Genentech Access Solutions helped **more than 290,000** people access the Genentech medicines they needed, and the Genentech Patient Foundation provided free medicine to **more than 51,000** people. In addition, **270,000** eligible patients were enrolled in Genentech Co-pay Assistance Programs in 2023.